Steakholder Foods Ltd. (STKH) Q2 2024 Earnings Call Transcript Summary
Steakholder Foods Ltd. (STKH) Q2 2024 Earnings Call Transcript Summary
General and administrative expenses dropped by 9% to $2 million.The following is a summary of the Steakholder Foods Ltd. (STKH) Q2 2024 Earnings Call Transcript:
以下是Steakholder Foods Ltd.（STKH）2024年第二季度業績會談話摘要：
Financial Performance:
金融業績：
In the first half of 2024, R&D costs were reduced to $1.6 million from $3.6 million in the previous year, a 54% decrease.
Marketing costs decreased by 56% to $700,000, from $1.6 million.
General and administrative expenses dropped by 9% to $2 million.
Net loss decreased by 54% to $4.4 million from $9.5 million in the first half of 2023.
Strong cash management with net cash used in operating activities reduced to $4.4 million from $7.5 million, and cash equivalents at the end of the period were $5.4 million compared to $4.2 million at the end of 2023.
2024年上半年，研發費用從去年的360萬美元降至160萬美元，同比減少54%。
營銷費用下降了56%，從160萬美元降至70萬美元。
總務和行政費用下降了9%，至200萬美元。
淨虧損從2023年上半年的950萬美元降至440萬美元，同比減少54%。
出色的現金管理，運營活動使用的淨現金從750萬美元降至440萬美元，期末現金及現金等價物爲540萬美元，較2023年末的420萬美元增加。
Business Progress:
業務進展：
Transitioned to commercialization with four strategic agreements signed, including with Wyler Farm, ITRI, Sherry Herring, and Premazon.
First commercial revenue expected by late 2024 or early 2025.
Continued focus on securing additional commercial deals and expanding market reach.
已簽署四項戰略協議，包括與Wyler Farm、ITRI、Sherry Herring和Premazon的協議，轉向商業化階段。
預計將於2024年年底或2025年初獲得第一個商業收入。
繼續專注於確保獲得額外的商業交易並擴大市場份額。
Opportunities:
機會：
Expansion into global markets is underway with strategic agreements, such as those with Wyler Farm and ITRI, bolstering an international presence and attracting further partners.
Transition from R&D phase to commercialization stage signifies shifting towards generating recurring revenue.
通過與Wyler Farm和ITRI等機構達成戰略協議，進一步擴展全球市場，並吸引更多合作伙伴。
從研發階段轉向商業化階段意味着轉向持續產生收入。
Risks:
風險：
Early stage of product rollout implies uncertainties in market acceptance and the scalability of the new product lines.
產品推出的早期階段意味着市場接受度和新產品線可擴展性存在不確定性。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
